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were HK$5,581 and HK$6,403 (1US $  7.8 HK $), re-
spectively. The cost-effectiveness ratios per ulcer-free pa-
tient were HK$6001 for triple-therapy arm and HK$8653
for naproxen group. CONCLUSION: H. pylori eradi-
cation therapy is cost-effective in preventing NSAID-
induced peptic ulcers in patients with positive H. pylori
infection.
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It has been shown that the combination of irinotecan
with fluorouracil is superior to fluorouracil alone in pa-
tients with advanced colorectal cancer as first-line ther-
apy. In a recent randomised trial (Douillard et al., Lan-
cet, 2000), median survival was 17.4 months for patients
treated with irinotecan combined with fluorouracil as
compared to 14.1 months in patients who received fluo-
rouracil alone. OBJECTIVE: The objective of the study is
to relate this statistically significant difference in overall
survival to differences in costs of each alternative.
METHODS: Medical care consumption data were col-
lected prospectively as part of the trial that included 387
patients. A further retrospective data collection was de-
signed to inform on further chemotherapy and disease
cost after study treatment failure. The perspective for the
calculation of cost was the French National Health Sys-
tem. Drug costs were assumed to be equal to public
prices. Hospital costs were derived from French public
DRG database. Consultation costs were abstracted from
the public tariff database. Censoring of medical care con-
sumption data was handled using the method described
by Lin et al. (Biometrics, 1997). Uncertainty will be ex-
plored through bootstrap analyses. RESULTS: The total
costs including drug cost, cost of treatment administration,
cost of the management of toxicities and cost of disease pro-
gression amounted to 182,000 FF (USD 26,500) per patient
treated with irinotecan and 123,000 FF (USD 18,000) per
patient treated with fluorouracil alone. When the difference
in cost is related to the clinical benefit of irinotecan, the cost
per life year saved amounted to 214,000 FF (USD 31,100).
Uncertainty analyses are ongoing and results will be pre-
sented. CONCLUSION: First-line therapy with irinotecan
extends significantly survival, at a cost that remains within
the limits currently accepted for new chemotherapeutic
agents. Robustness of this conclusion to uncertainty is cur-
rently under investigation.
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OBJECTIVE: To investigate the relationship between
quality adjusted life years (QALYs) and willingness to
pay (WTP) in acute and chronic conditions. METHODS:
Two face-to-face interviews were conducted one week
apart in a convenience sample of women aged 22 to 50
years with no history of breast cancer or cancer requiring
chemotherapy (n  119). Data were collected between
3/2000 to 6/2000 at The Ohio State University. Study
participation required completion of two surveys: one
evaluating utility for an acute condition (post chemother-
apy nausea and vomiting: PCNV), and the other assess-
ing utility in a chronic condition (breast cancer). Utility
was assessed using: WTP, and visual analogue scale
(VAS) and standard gamble (SG) methods were used to
estimate QALYs. Since QALYs and WTP were purported
to be based on the same underlying theoretical founda-
tions in welfare economics, WTP was regressed on
QALYs, age, income and health status, for acute and
chronic health interventions using natural log transfor-
mations of WTP and QALY. RESULTS: Regression anal-
ysis reported statistically significant models for breast
cancer cure and treatment respectively (Adjusted R2 
0.245, P  0.001; Adjusted R2  0.287, P  0.001) and
PCNV standard and optimal therapy (Adjusted R2 
0.01, P  0.003 and Adjusted R2  0.01, P  0.003).
CONCLUSION: The results of this study indicate that
QALY is a better predictor of WTP for chronic condi-
tions; however, QALY is not a good predictor of WTP
for acute conditions. This could be attributed to viola-
tions of underlying assumptions in measurement of QALYs.
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INTRODUCTION: Capecitabine is an oral fluoropyrim-
idine, which mimics continuous 5-FU and is preferen-
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tially activated by thymidine phosphorylase to 5-FU
within tumor cells. A randomized phase III clinical trial
comparing capecitabine (n  301, 1250 mg/m2/bid 

14d, q3 weeks) vs. Mayo Clinic (M)-regimen (n  301,
5-FU 425 mg/m2; LCV 20 mg/m2 d1-5, q4 weeks) re-
sulted in a superior response rate (26.6% vs. 17.9%, P 
0.013), equivalent progression-free survival (5.3 vs 4.8
months, HR (hazard ratio) 0.96), equivalent overall sur-
vival (13.2 vs 12.4 months, HR 0.91), and a superior
safety profile in terms of significantly less gastrointestinal
toxicity, neutropenia and alopecia for capecitabine. OB-
JECTIVE: To evaluate the economic consequences of oral
capecitabine vs. i.v. M-regimen administration. METHODS:
Patients were recruited from 66 centers in 8 EU-coun-
tries, Australia, New Zealand, Russia, Israel and Taiwan.
Data on number and duration of visits for drug adminis-
tration were collected during the clinical trial for all ran-
domized patients and analyzed. Cost estimates based on
publicly available statistics were used. RESULTS: For
capecitabine, one visit per cycle (every 21 days) was sched-
uled and 5 per cycle (every 28 days) for the M-regimen.
Overall, 73% of scheduled visits (for drug administra-
tion) were avoided. In all countries, with the exception of
Germany, the M-regimen was administered as an outpa-
tient treatment (96.8%–100%). In Germany 40% of all
M-regimen administrations involved overnight stays in
the hospital. Savings per patient in the range of €2,200
(UK outpatient) and €8,000 (Germany in-patient) may be
expected due to capecitabines’ oral route of administra-
tion. CONCLUSION: Oral administration of capecita-
bine substantially reduces the number of visits cancer
patients make to treating centers compared to i.v. admin-
istration (M-regimen). 73% of drug administration visits
were avoided in this phase III study. Improvements in
patient convenience and considerable savings to the
healthcare system can be realized with oral drug adminis-
tration.
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OBJECTIVE: To observe patterns of antidepressant use
and concomitant psychotropics to determine implications
for clinical prescribing practice. METHOD: Among 1.6
million members of Merck-Medco Managed Care, L.L.C.
followed continuously between 1/1/96 and 12/31/98, we
identified all patients (N  42,510) who received a new
prescription (defined as none within the prior 12 months)
for an antidepressant in 1997 (Index AD). We observed
the time between the use of other concomitant psychotro-
pics (e.g. antipsychotics(AP)/atypicals(AP-A), anxiolytics
(ANX)/buspirone(ANX-B), sedative/hypnotics (SH) and
zolipidem (SH-Z), and miscellaneous (MISC)) in the year
prior to or after the index AD prescription. RESULTS:
14, 792 (34.8%) of AD patients used a concomitant psy-
chotropic. These patients displayed a parallel pattern in
use of all classes of concomitants: 0.2–12.2% using at
least one additional class 4 months prior to, 0.3–2.0%
same day, and 0.8–3.0% 4 months after the index antide-
pressant. However, patients were more likely to receive a
traditional antipsychotic and anxiolytic prior to the in-
dex AD, and an atypical antipsychotic and buspirone af-
ter the index AD.
Concomitant % of ADpatients
Pre Index
AD
Same
Day
Post Index
AD
AP 2.3 .7 .3 1.3
AP-A 2.4 .2 .4 1.8
ANX 21.3 12.2 2.0 7.1
ANX-B 3.7 1.5 .4 1.8
MISC 2.6 .7 .3 .8
SH 5.7 3.0 .4 2.3
SH-Z 9.0 4.4 .7 3.0
CONCLUSION: Whereas we hypothesized excessive
benzodiazepine and hypnotic usage pre and post index
AD, we noted lower than expected usage. We did not ex-
pect the pattern of increased atypical antipsychotic usage
on the same day or subsequent to an index AD. All
classes of concomitant psychotropics revealed a similar
general pattern: a steady increase in the 4 months prior to
an index AD, a peak on the index AD date, and a taper-
ing over the next 4 months. We speculate that continuing
medical education of physicians may be contributing to a
decrease in the misuse of benzodiazepines and sedative/
hypnotics.
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OBJECTIVES: To assess the risk of diabetes among pa-
tients undergoing treatment with risperidone vs olanza-
pine. A series of case reports had previously associated
olanzapine use with the development of hyperglycemia,
diabetes, and diabetic ketoacidosis. METHODS: Two
cohorts totaling 34,713 patients were identified from the
Quebec Medicare database between January 1997 and
31st December 1999. One cohort consisted of patients
who had at least one prescription for olanzapine during
that period (n  19,779) and the other of patients receiv-
ing risperidone but not olanzapine (n  14,934). In ei-
ther case, patients with a diagnosis of diabetes (defined as
either a recorded ICD9 250.0 to 250.93 or a prescription
